Navigation Links
Taipan venom no snake oil

Australian snakes' venom could provide the next generation of human therapeutic drugs.

A blood-clotting protein in taipan venom has been identified by Queensland University of Technology PhD researcher Liam St Pierre to rapidly stop excessive bleeding during vascular surgery and major trauma.

The genetic code for the toxin, Factor X (Factor Ten), was identified by PhD researcher Liam St Pierre from QUT's School of Life Sciences who studied the venom of eight of Australia's deadliest land snakes for their therapeutic potential.

His study focussed on the genes in the coastal taipan's venom that are responsible for the pro coagulant or blood clotting agent called Factor X which could stem blood flow in a matter of seconds.

A drug lead based on Factor X is being evaluated for clinical trials by bio pharmaceutical development company QRxPharma.

"Australian snakes literally have a two-pronged attack when they bite their prey," Dr St Pierre said.

"Firstly, venom injection causes massive blood clots instantaneously followed by paralysis as a result of neurotoxins which eventually immobilise and kill the victim."

Dr St Pierre said mammals and snakes naturally produced a small amount of Factor X in their livers.

"Snakes produce a more stable and faster acting form of Factor X in their venom which is the only source of Factor X other than mammalian livers," he said.

"They have developed the ability to deliver massive fatal doses of Factor X to specifically target the systems ofmammals."

Dr St Pierre studied the venom of the inland and coastal taipan, the common brown, the red bellied black, the mulga, the rough-scaled snake, Stephens banded snake and the tiger snake.

"Only the mulga did not have Factor X as it has developed its own unique mechanism of killing."

Dr St Pierre said snake venom was a huge untapped source of potential drug therapies.

His study is the most detailed ever conducted on the genes responsible for Australian snakes' toxins. It is hoped a comprehensive study of all the venom components from Australian snakes may yield further novel components thatcould be targeted as human drugs.


'"/>

Source:Research Australia


Related biology news :

1. Researchers find first evidence of venom system in extinct mammal
2. Evolution mystery: Spider venom and bacteria share same toxin
3. Stanford snake venom study shows that certain cells may eliminate poison
4. Radioactive scorpion venom for fighting cancer
5. Tarantula venom and chili peppers target same pain sensor
6. Nonvenomous Asian snakes borrow defensive poison from toxic toads
7. Venom doc tracks down snake bioweapons
8. Researchers reveal secrets of flying snakes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology: